Abiopharma

🔍 Nelson Shawn David (Director)

Company: Lovesac Co (LOVE)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 4,848 shares of Common Stock, $0.00001 par value (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 203,219.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,197 shares of Common Stock, $0.00001 par value at $16.65 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 201,022.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 17,066 shares of Common Stock, $0.00001 par value (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 218,088.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 7,731 shares of Common Stock, $0.00001 par value at $16.65 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 210,357.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 2,040 shares of Common Stock, $0.00001 par value at $16.65 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 208,317.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 7,113 shares of Common Stock, $0.00001 par value at $16.65 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 201,204.00 | transaction_form_type: 4 | Footnotes: F6
• Holds 0 shares of Common Stock, $0.00001 par value (Direct)
  Date: 2026-04-15 | Code: H | nature_of_ownership: The LPDV Holding Trust | shares_owned_after: 52,094.00 | Footnotes: F7
• Acquired 77,701 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 77,701.00 | transaction_form_type: 4 | Footnotes: F8, F9, F9
• Acquired 77,701 shares of Restricted Stock Units (Performance-based Vesting) (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 77,701.00 | transaction_form_type: 4 | Footnotes: F8, F10, F10
• Sold 4,848 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F8, F1, F1
• Sold 17,066 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 34,134.00 | transaction_form_type: 4 | Footnotes: F8, F3, F3

Footnotes:

• F1: The reported shares were acquired upon the vesting of the third tranche of time-based restricted stock units ("RSUs") granted on April 15, 2023.
• F2: The reported shares were withheld to satisfy the Reporting Person's tax liability in connection with the settlement of the third tranche of time-based RSUs granted on April 15, 2023. No shares were sold.
• F3: The reported shares were acquired upon the vesting of the first tranche of time-based RSUs granted on April 15, 2025.
• F4: The reported shares were withheld to satisfy the Reporting Person's tax liability in connection with the settlement of the first tranche of time-based RSUs granted on April 15, 2025. No shares were sold.
• F5: The reported shares were withheld to satisfy the Reporting Person's tax liability in connection with the settlement of a portion of the third tranche of performance-based RSUs granted on April 15, 2023. No shares were sold.
• F6: The reported shares were withheld to satisfy the Reporting Person's tax liability in connection with the settlement of a portion of the first tranche of performance-based RSUs granted on April 15, 2025. No shares were sold.
• F7: The reported shares are held by The LDPV Holding Trust, dated October 1, 2018, of which the reporting person's spouse is trustee and the reporting person has sole authority over the disposition of the shares of the Issuer held by the trust.
• F8: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
• F9: On April 15, 2026, the Reporting Person received a grant of RSUs which vest in three equal installments on the first, second and third anniversaries of the grant date.
• F10: On April 15, 2026, the Reporting Person received a grant of performance-based RSUs which vest based on the Issuer's achievements with respect to certain pre-established performance targets for the performance period. Once earned, the performance-based RSUs are payable at the end of the three-year performance period.